SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kintara Therapeutics, Inc. – ‘S-4/A’ on 7/1/20 – ‘XML’

On:  Wednesday, 7/1/20, at 7:59pm ET   ·   As of:  7/2/20   ·   Accession #:  1193125-20-185478   ·   File #:  333-239215

Previous ‘S-4’:  ‘S-4’ on 6/16/20   ·   Next & Latest:  ‘S-4’ on 5/13/24   ·   12 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/02/20  DelMar Pharmaceuticals, Inc.      S-4/A       7/01/20   76:11M                                    Donnelley … Solutions/FA

Pre-Effective Amendment to Registration of Securities Issued in a Merger   —   Form S-4
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-4/A       Pre-Effective Amendment to Registration of          HTML   3.41M 
                Securities Issued in a Business-Combination                      
                Transaction                                                      
 2: EX-5.1      Opinion of Counsel re: Legality                     HTML     31K 
 3: EX-8.1      Opinion of Counsel re: Tax Matters                  HTML     29K 
 4: EX-10.43    Material Contract                                   HTML    102K 
 5: EX-23.3     Consent of Experts or Counsel                       HTML     23K 
 6: EX-23.4     Consent of Experts or Counsel                       HTML     22K 
 7: EX-99.1     Miscellaneous Exhibit                               HTML     29K 
 8: EX-99.2     Miscellaneous Exhibit                               HTML     26K 
 9: EX-99.3     Miscellaneous Exhibit                               HTML     23K 
10: EX-99.4     Miscellaneous Exhibit                               HTML     23K 
17: R1          Cover                                               HTML     38K 
18: R2          Condensed Consolidated Interim Balance Sheets       HTML     86K 
19: R3          Condensed Consolidated Interim Balance Sheets       HTML     45K 
                (Parenthetical)                                                  
20: R4          Condensed Consolidated Interim Statements of        HTML     68K 
                Operations                                                       
21: R5          Condensed Consolidated Interim Statements of        HTML    143K 
                Stockholders' Equity                                             
22: R6          Condensed Consolidated Interim Statements of Cash   HTML     88K 
                Flows                                                            
23: R7          Nature of Operations, Corporate History, and Going  HTML     44K 
                Concern                                                          
24: R8          Significant accounting policies                     HTML     91K 
25: R9          Valent Technologies LLC agreements                  HTML     29K 
26: R10         Derivative liabilities                              HTML     64K 
27: R11         Stockholders' equity                                HTML    218K 
28: R12         Related party transactions                          HTML     29K 
29: R13         Current and deferred income taxes                   HTML     46K 
30: R14         Commitments and contingencies                       HTML     29K 
31: R15         Supplementary statement of cash flows information   HTML     35K 
32: R16         Financial risk management                           HTML     39K 
33: R17         Subsequent events                                   HTML     46K 
34: R18         Financial instruments                               HTML     34K 
35: R19         Significant accounting policies (Policies)          HTML    142K 
36: R20         Significant accounting policies (Tables)            HTML     30K 
37: R21         Derivative liabilities (Tables)                     HTML     60K 
38: R22         Stockholders' equity (Tables)                       HTML    185K 
39: R23         Current and deferred income taxes (Tables)          HTML     44K 
40: R24         Supplementary statement of cash flows information   HTML     34K 
                (Tables)                                                         
41: R25         Financial risk management (Tables)                  HTML     33K 
42: R26         Nature of Operations, Corporate History, and Going  HTML     42K 
                Concern (Detail)                                                 
43: R27         Significant Accounting Policies (Detail)            HTML     69K 
44: R28         Significant accounting policies - Schedule of       HTML     30K 
                derivative liabilities under the fair value                      
                hierarchy (Detail)                                               
45: R29         Valent Technologies LLC Agreements - Additional     HTML     44K 
                Information (Detail)                                             
46: R30         Derivative Liabilities - Additional Information     HTML     56K 
                (Detail)                                                         
47: R31         Derivative Liabilities - Schedule of derivative     HTML     43K 
                liabilities (Detail)                                             
48: R32         Derivative Liabilities - Schedule of derivative     HTML     47K 
                liabilities 1 (Detail)                                           
49: R33         Stockholders' Equity (Deficiency) (Textual)         HTML    133K 
                (Detail)                                                         
50: R34         Stockholders' Equity (Deficiency) (Textual 2)       HTML     86K 
                (Detail)                                                         
51: R35         Stockholders' Equity (Deficiency) (Textual 3)       HTML    131K 
                (Detail)                                                         
52: R36         Stockholders' equity (deficiency) - Schedule of     HTML     55K 
                outstanding under the legacy plan (Detail)                       
53: R37         Stockholders' Equity (Deficiency) - Schedule of     HTML     49K 
                valuation assumptions using a Black-Scholes                      
                pricing model (Detail)                                           
54: R38         Stockholders' equity (deficiency) - Summary of      HTML    106K 
                stock options currently outstanding and                          
                exercisable (Detail)                                             
55: R39         Stockholders' Equity (Deficiency) - (Textual 4)     HTML     84K 
                (Detail)                                                         
56: R40         Stockholders' equity (deficiency) - Schedule of     HTML     34K 
                stock-based compensation expense (Detail)                        
57: R41         Stockholders' equity (deficiency) - Summary of      HTML     51K 
                unvested stock options (Detail)                                  
58: R42         Stockholders' Equity (Deficiency) - Schedule of     HTML     75K 
                warrants (Detail)                                                
59: R43         Stockholders' Equity (Deficiency) - Schedule of     HTML     46K 
                warrants (Parenthetical) (Detail)                                
60: R44         Stockholders' Equity (Deficiency - Summary of       HTML     39K 
                changes in outstanding warrants (Detail)                         
61: R45         Stockholders' Equity (Deficiency) - Summary of      HTML     86K 
                outstanding warrants (Detail)                                    
62: R46         Related Party Transactions - Additional             HTML     32K 
                Information (Detail)                                             
63: R47         Current and Deferred Income Taxes - Components of   HTML     50K 
                future tax assets and deferred tax liabilities                   
                (Detail)                                                         
64: R48         Current and Deferred Income Taxes - Additional      HTML     52K 
                Information (Detail)                                             
65: R49         Current and Deferred Income Taxes - Schedule of     HTML     47K 
                difference between income tax rate and statutory                 
                income tax rate (Detail)                                         
66: R50         Commitments and Contingencies - Additional          HTML     33K 
                Information (Detail)                                             
67: R51         Supplementary Statement of Cash Flows Information   HTML     40K 
                - Schedule of supplementary statement of cash                    
                flows information (Detail)                                       
68: R52         Financial Risk Management - Additional Information  HTML     50K 
                (Detail)                                                         
69: R53         Financial Risk Management - Schedule of balances    HTML     32K 
                in foreign currencies (Detail)                                   
70: R54         Financial Risk Management - Schedule of fair value  HTML     32K 
                of off-balance sheet risks (Detail)                              
71: R55         Subsequent Events - Additional Information          HTML    112K 
                (Detail)                                                         
72: R56         Stockholders' Equity - Schedule of Conversion of    HTML     36K 
                Series B Preferred stock to common stock (Detail)                
73: R57         Financial Instruments - Additional Information      HTML     26K 
                (Detail)                                                         
75: XML         IDEA XML File -- Filing Summary                      XML    132K 
74: EXCEL       IDEA Workbook of Financial Reports                  XLSX    113K 
11: EX-101.INS  XBRL Instance -- dmpi-20200331                       XML   2.13M 
13: EX-101.CAL  XBRL Calculations -- dmpi-20200331_cal               XML    145K 
14: EX-101.DEF  XBRL Definitions -- dmpi-20200331_def                XML    762K 
15: EX-101.LAB  XBRL Labels -- dmpi-20200331_lab                     XML   1.39M 
16: EX-101.PRE  XBRL Presentations -- dmpi-20200331_pre              XML   1.05M 
12: EX-101.SCH  XBRL Schema -- dmpi-20200331                         XSD    236K 
76: ZIP         XBRL Zipped Folder -- 0001193125-20-185478-xbrl      Zip    205K

‘XML’   —   IDEA XML File — Filing Summary

This Document is an IDEA XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<FilingSummary>
<Version> 3.20.2 </Version>
<ProcessingTime/>
<ReportFormat> html </ReportFormat>
<ContextCount> 417 </ContextCount>
<ElementCount> 430 </ElementCount>
<EntityCount> 1 </EntityCount>
<FootnotesReported> true </FootnotesReported>
<SegmentCount> 97 </SegmentCount>
<ScenarioCount> 0 </ScenarioCount>
<TuplesReported> false </TuplesReported>
<UnitCount> 5 </UnitCount>
<MyReports>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R1.htm </HtmlFileName>
<LongName> 101 - Document - Cover </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/Cover </Role>
<ShortName> Cover </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 1 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R2.htm </HtmlFileName>
<LongName> 103 - Statement - Condensed Consolidated Interim Balance Sheets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/StatementOfFinancialPositionClassified </Role>
<ShortName> Condensed Consolidated Interim Balance Sheets </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 2 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R3.htm </HtmlFileName>
<LongName> 104 - Statement - Condensed Consolidated Interim Balance Sheets (Parenthetical) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical </Role>
<ShortName> Condensed Consolidated Interim Balance Sheets (Parenthetical) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 3 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R4.htm </HtmlFileName>
<LongName> 105 - Statement - Condensed Consolidated Interim Statements of Operations </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/StatementOfIncomeAlternative </Role>
<ShortName> Condensed Consolidated Interim Statements of Operations </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 4 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R5.htm </HtmlFileName>
<LongName> 106 - Statement - Condensed Consolidated Interim Statements of Stockholders' Equity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome </Role>
<ShortName> Condensed Consolidated Interim Statements of Stockholders' Equity </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 5 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R6.htm </HtmlFileName>
<LongName> 107 - Statement - Condensed Consolidated Interim Statements of Cash Flows </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/StatementOfCashFlowsIndirect </Role>
<ShortName> Condensed Consolidated Interim Statements of Cash Flows </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 6 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R7.htm </HtmlFileName>
<LongName> 108 - Disclosure - Nature of Operations, Corporate History, and Going Concern </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations </Role>
<ShortName> Nature of Operations, Corporate History, and Going Concern </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 7 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R8.htm </HtmlFileName>
<LongName> 109 - Disclosure - Significant accounting policies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock </Role>
<ShortName> Significant accounting policies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 8 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R9.htm </HtmlFileName>
<LongName> 110 - Disclosure - Valent Technologies LLC agreements </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsValentTechnologiesLlcTextBlock </Role>
<ShortName> Valent Technologies LLC agreements </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 9 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R10.htm </HtmlFileName>
<LongName> 111 - Disclosure - Derivative liabilities </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock </Role>
<ShortName> Derivative liabilities </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 10 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R11.htm </HtmlFileName>
<LongName> 112 - Disclosure - Stockholders' equity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock </Role>
<ShortName> Stockholders' equity </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 11 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R12.htm </HtmlFileName>
<LongName> 113 - Disclosure - Related party transactions </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock </Role>
<ShortName> Related party transactions </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 12 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R13.htm </HtmlFileName>
<LongName> 114 - Disclosure - Current and deferred income taxes </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock </Role>
<ShortName> Current and deferred income taxes </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 13 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R14.htm </HtmlFileName>
<LongName> 115 - Disclosure - Commitments and contingencies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock </Role>
<ShortName> Commitments and contingencies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 14 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R15.htm </HtmlFileName>
<LongName> 116 - Disclosure - Supplementary statement of cash flows information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock </Role>
<ShortName> Supplementary statement of cash flows information </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 15 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R16.htm </HtmlFileName>
<LongName> 117 - Disclosure - Financial risk management </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsConcentrationRiskDisclosureTextBlock </Role>
<ShortName> Financial risk management </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 16 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R17.htm </HtmlFileName>
<LongName> 118 - Disclosure - Subsequent events </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock </Role>
<ShortName> Subsequent events </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 17 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R18.htm </HtmlFileName>
<LongName> 119 - Disclosure - Financial instruments </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsFinancialInstrumentsDisclosureTextBlock </Role>
<ShortName> Financial instruments </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 18 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R19.htm </HtmlFileName>
<LongName> 120 - Disclosure - Significant accounting policies (Policies) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockPolicies </Role>
<ShortName> Significant accounting policies (Policies) </ShortName>
<MenuCategory> Policies </MenuCategory>
<Position> 19 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R20.htm </HtmlFileName>
<LongName> 121 - Disclosure - Significant accounting policies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlockTables </Role>
<ShortName> Significant accounting policies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock </ParentRole>
<Position> 20 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R21.htm </HtmlFileName>
<LongName> 122 - Disclosure - Derivative liabilities (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlockTables </Role>
<ShortName> Derivative liabilities (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsDerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock </ParentRole>
<Position> 21 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R22.htm </HtmlFileName>
<LongName> 123 - Disclosure - Stockholders' equity (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables </Role>
<ShortName> Stockholders' equity (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock </ParentRole>
<Position> 22 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R23.htm </HtmlFileName>
<LongName> 124 - Disclosure - Current and deferred income taxes (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables </Role>
<ShortName> Current and deferred income taxes (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock </ParentRole>
<Position> 23 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R24.htm </HtmlFileName>
<LongName> 125 - Disclosure - Supplementary statement of cash flows information (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables </Role>
<ShortName> Supplementary statement of cash flows information (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock </ParentRole>
<Position> 24 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R25.htm </HtmlFileName>
<LongName> 126 - Disclosure - Financial risk management (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsConcentrationRiskDisclosureTextBlockTables </Role>
<ShortName> Financial risk management (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsConcentrationRiskDisclosureTextBlock </ParentRole>
<Position> 25 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R26.htm </HtmlFileName>
<LongName> 127 - Disclosure - Nature of Operations, Corporate History, and Going Concern (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureNatureOfOperationsCorporateHistoryAndGoingConcern </Role>
<ShortName> Nature of Operations, Corporate History, and Going Concern (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations </ParentRole>
<Position> 26 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R27.htm </HtmlFileName>
<LongName> 128 - Disclosure - Significant Accounting Policies (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureSignificantAccountingPolicies </Role>
<ShortName> Significant Accounting Policies (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 27 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R28.htm </HtmlFileName>
<LongName> 129 - Disclosure - Significant accounting policies - Schedule of derivative liabilities under the fair value hierarchy (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfDerivativeLiabilitiesUnderTheFairValueHierarchy </Role>
<ShortName> Significant accounting policies - Schedule of derivative liabilities under the fair value hierarchy (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 28 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R29.htm </HtmlFileName>
<LongName> 130 - Disclosure - Valent Technologies LLC Agreements - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureValentTechnologiesLLCAgreementsAdditionalInformation </Role>
<ShortName> Valent Technologies LLC Agreements - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 29 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R30.htm </HtmlFileName>
<LongName> 131 - Disclosure - Derivative Liabilities - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureDerivativeLiabilitiesAdditionalInformation </Role>
<ShortName> Derivative Liabilities - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 30 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R31.htm </HtmlFileName>
<LongName> 132 - Disclosure - Derivative Liabilities - Schedule of derivative liabilities (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureDerivativeLiabilitiesScheduleOfDerivativeLiabilities </Role>
<ShortName> Derivative Liabilities - Schedule of derivative liabilities (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 31 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R32.htm </HtmlFileName>
<LongName> 133 - Disclosure - Derivative Liabilities - Schedule of derivative liabilities 1 (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureDerivativeLiabilitiesScheduleOfDerivativeLiabilities1 </Role>
<ShortName> Derivative Liabilities - Schedule of derivative liabilities 1 (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 32 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R33.htm </HtmlFileName>
<LongName> 134 - Disclosure - Stockholders' Equity (Deficiency) (Textual) (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencyTextual </Role>
<ShortName> Stockholders' Equity (Deficiency) (Textual) (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 33 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R34.htm </HtmlFileName>
<LongName> 135 - Disclosure - Stockholders' Equity (Deficiency) (Textual 2) (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencyTextual2 </Role>
<ShortName> Stockholders' Equity (Deficiency) (Textual 2) (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 34 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R35.htm </HtmlFileName>
<LongName> 136 - Disclosure - Stockholders' Equity (Deficiency) (Textual 3) (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencyTextual3 </Role>
<ShortName> Stockholders' Equity (Deficiency) (Textual 3) (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 35 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R36.htm </HtmlFileName>
<LongName> 137 - Disclosure - Stockholders' equity (deficiency) - Schedule of outstanding under the legacy plan (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquitydeficiencyScheduleOfOutstandingUnderTheLegacyPlan </Role>
<ShortName> Stockholders' equity (deficiency) - Schedule of outstanding under the legacy plan (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables </ParentRole>
<Position> 36 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R37.htm </HtmlFileName>
<LongName> 138 - Disclosure - Stockholders' Equity (Deficiency) - Schedule of valuation assumptions using a Black-Scholes pricing model (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencyScheduleOfValuationAssumptionsUsingABlackScholesPricingModel </Role>
<ShortName> Stockholders' Equity (Deficiency) - Schedule of valuation assumptions using a Black-Scholes pricing model (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 37 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R38.htm </HtmlFileName>
<LongName> 139 - Disclosure - Stockholders' equity (deficiency) - Summary of stock options currently outstanding and exercisable (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquitydeficiencySummaryOfStockOptionsCurrentlyOutstandingAndExercisable </Role>
<ShortName> Stockholders' equity (deficiency) - Summary of stock options currently outstanding and exercisable (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables </ParentRole>
<Position> 38 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R39.htm </HtmlFileName>
<LongName> 140 - Disclosure - Stockholders' Equity (Deficiency) - (Textual 4) (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencyTextual4 </Role>
<ShortName> Stockholders' Equity (Deficiency) - (Textual 4) (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 39 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R40.htm </HtmlFileName>
<LongName> 141 - Disclosure - Stockholders' equity (deficiency) - Schedule of stock-based compensation expense (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquitydeficiencyScheduleOfStockbasedCompensationExpense </Role>
<ShortName> Stockholders' equity (deficiency) - Schedule of stock-based compensation expense (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables </ParentRole>
<Position> 40 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R41.htm </HtmlFileName>
<LongName> 142 - Disclosure - Stockholders' equity (deficiency) - Summary of unvested stock options (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquitydeficiencySummaryOfUnvestedStockOptions </Role>
<ShortName> Stockholders' equity (deficiency) - Summary of unvested stock options (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.delmarpharma.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables </ParentRole>
<Position> 41 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R42.htm </HtmlFileName>
<LongName> 143 - Disclosure - Stockholders' Equity (Deficiency) - Schedule of warrants (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencyScheduleOfWarrants </Role>
<ShortName> Stockholders' Equity (Deficiency) - Schedule of warrants (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 42 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R43.htm </HtmlFileName>
<LongName> 144 - Disclosure - Stockholders' Equity (Deficiency) - Schedule of warrants (Parenthetical) (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencyScheduleOfWarrantsParenthetical </Role>
<ShortName> Stockholders' Equity (Deficiency) - Schedule of warrants (Parenthetical) (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 43 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R44.htm </HtmlFileName>
<LongName> 145 - Disclosure - Stockholders' Equity (Deficiency - Summary of changes in outstanding warrants (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencySummaryOfChangesInOutstandingWarrants </Role>
<ShortName> Stockholders' Equity (Deficiency - Summary of changes in outstanding warrants (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 44 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R45.htm </HtmlFileName>
<LongName> 146 - Disclosure - Stockholders' Equity (Deficiency) - Summary of outstanding warrants (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityDeficiencySummaryOfOutstandingWarrants </Role>
<ShortName> Stockholders' Equity (Deficiency) - Summary of outstanding warrants (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 45 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R46.htm </HtmlFileName>
<LongName> 147 - Disclosure - Related Party Transactions - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation </Role>
<ShortName> Related Party Transactions - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 46 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R47.htm </HtmlFileName>
<LongName> 148 - Disclosure - Current and Deferred Income Taxes - Components of future tax assets and deferred tax liabilities (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureCurrentAndDeferredIncomeTaxesComponentsOfFutureTaxAssetsAndDeferredTaxLiabilities </Role>
<ShortName> Current and Deferred Income Taxes - Components of future tax assets and deferred tax liabilities (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 47 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R48.htm </HtmlFileName>
<LongName> 149 - Disclosure - Current and Deferred Income Taxes - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureCurrentAndDeferredIncomeTaxesAdditionalInformation </Role>
<ShortName> Current and Deferred Income Taxes - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 48 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R49.htm </HtmlFileName>
<LongName> 150 - Disclosure - Current and Deferred Income Taxes - Schedule of difference between income tax rate and statutory income tax rate (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureCurrentAndDeferredIncomeTaxesScheduleOfDifferenceBetweenIncomeTaxRateAndStatutoryIncomeTaxRate </Role>
<ShortName> Current and Deferred Income Taxes - Schedule of difference between income tax rate and statutory income tax rate (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 49 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R50.htm </HtmlFileName>
<LongName> 151 - Disclosure - Commitments and Contingencies - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation </Role>
<ShortName> Commitments and Contingencies - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 50 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R51.htm </HtmlFileName>
<LongName> 152 - Disclosure - Supplementary Statement of Cash Flows Information - Schedule of supplementary statement of cash flows information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureSupplementaryStatementOfCashFlowsInformationScheduleOfSupplementaryStatementOfCashFlowsInformation </Role>
<ShortName> Supplementary Statement of Cash Flows Information - Schedule of supplementary statement of cash flows information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 51 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R52.htm </HtmlFileName>
<LongName> 153 - Disclosure - Financial Risk Management - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureFinancialRiskManagementAdditionalInformation </Role>
<ShortName> Financial Risk Management - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 52 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R53.htm </HtmlFileName>
<LongName> 154 - Disclosure - Financial Risk Management - Schedule of balances in foreign currencies (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfBalancesInForeignCurrencies </Role>
<ShortName> Financial Risk Management - Schedule of balances in foreign currencies (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 53 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R54.htm </HtmlFileName>
<LongName> 155 - Disclosure - Financial Risk Management - Schedule of fair value of off-balance sheet risks (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureFinancialRiskManagementScheduleOfFairValueOfOffbalanceSheetRisks </Role>
<ShortName> Financial Risk Management - Schedule of fair value of off-balance sheet risks (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 54 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R55.htm </HtmlFileName>
<LongName> 156 - Disclosure - Subsequent Events - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation </Role>
<ShortName> Subsequent Events - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 55 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R56.htm </HtmlFileName>
<LongName> 157 - Disclosure - Stockholders' Equity - Schedule of Conversion of Series B Preferred stock to common stock (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureStockholdersEquityScheduleOfConversionOfSeriesBPreferredStockToCommonStock </Role>
<ShortName> Stockholders' Equity - Schedule of Conversion of Series B Preferred stock to common stock (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 56 </Position>
</Report>
<Report instance="dmpi-20200331.xml">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R57.htm </HtmlFileName>
<LongName> 158 - Disclosure - Financial Instruments - Additional Information (Detail) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.delmarpharma.com/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformation </Role>
<ShortName> Financial Instruments - Additional Information (Detail) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 57 </Position>
</Report>
<Report>
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<LongName> All Reports </LongName>
<ReportType> Book </ReportType>
<ShortName> All Reports </ShortName>
</Report>
</MyReports>
<InputFiles>
<File> dmpi-20200331.xml </File>
<File> dmpi-20200331.xsd </File>
<File> dmpi-20200331_cal.xml </File>
<File> dmpi-20200331_def.xml </File>
<File> dmpi-20200331_lab.xml </File>
<File> dmpi-20200331_pre.xml </File>
</InputFiles>
<SupplementalFiles/>
<BaseTaxonomies>
<BaseTaxonomy> http://fasb.org/srt/2019-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://xbrl.sec.gov/country/2017-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://fasb.org/us-gaap/2019-01-31 </BaseTaxonomy>
<BaseTaxonomy> http://xbrl.sec.gov/dei/2019-01-31 </BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase> true </HasPresentationLinkbase>
<HasCalculationLinkbase> true </HasCalculationLinkbase>
</FilingSummary>

12 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 5/13/24  Kintara Therapeutics, Inc.        S-4                   28:10M                                    Donnelley … Solutions/FA
10/27/23  Kintara Therapeutics, Inc.        S-1/A                 12:1.2M                                   Donnelley … Solutions/FA
10/24/23  Kintara Therapeutics, Inc.        S-1/A                 20:2.4M                                   Donnelley … Solutions/FA
10/04/23  Kintara Therapeutics, Inc.        S-1                   13:1.1M                                   Donnelley … Solutions/FA
 9/18/23  Kintara Therapeutics, Inc.        10-K        6/30/23   75:12M                                    Donnelley … Solutions/FA
 9/27/22  Kintara Therapeutics, Inc.        10-K        6/30/22   79:15M                                    Donnelley … Solutions/FA
 9/28/21  Kintara Therapeutics, Inc.        10-K        6/30/21   79:13M                                    ActiveDisclosure/FA
10/26/20  Kintara Therapeutics, Inc.        S-3                    4:1.5M                                   ActiveDisclosure/FA
 9/18/20  Kintara Therapeutics, Inc.        10-K        6/30/20   71:9.9M                                   ActiveDisclosure/FA
 9/01/20  Kintara Therapeutics, Inc.        8-K:1,3,5,7 8/31/20    4:300K                                   EdgarAgents LLC/FA
 8/25/20  Kintara Therapeutics, Inc.        8-K:1,3,5,7 8/20/20    4:190K                                   EdgarAgents LLC/FA
 8/21/20  Kintara Therapeutics, Inc.        8-K:1,2,3,5 8/17/20    8:1.4M                                   EdgarAgents LLC/FA
↑Top
Filing Submission 0001193125-20-185478   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Thu., May 16, 3:39:41.1pm ET